基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics.
Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
利用影像组学评估乳腺癌患者TIL(肿瘤浸润淋巴细胞)的研究较少。
建立基于动态对比增强(DCE)磁共振成像(MRI)的影像组学列线图,用于术前评估TIL水平。研究类型:回顾性。研究对象:共154例乳腺癌患者,分入训练队列(N=87)和测试队列(N=67);根据组织病理学结果进一步分为低TIL(<50%)和高TIL(≥50%)亚组。磁场强度/序列:3.0 T;轴位T2加权成像(快速自旋回波)、弥散加权成像(自旋回波-回波平面成像)以及乳腺容积成像DCE序列(梯度回波)。评估:利用训练数据集构建影像组学特征,并通过多变量逻辑回归筛选独立危险因素以建立临床模型。结合影像组学评分和危险因素构建列线图模型。采用校准曲线和决策曲线评估列线图性能。计算受试者工作特征(ROC)曲线下面积、准确度、敏感度和特异度。统计检验:进行最小绝对收缩与选择算子分析、单变量和多变量逻辑回归分析、t检验、卡方检验或Fisher精确检验、Hosmer-Lemeshow检验、ROC分析和决策曲线分析。P<0.05被认为具有统计学意义。
与临床模型(训练集AUC 0.76;测试集AUC 0.72)相比,影像组学特征和列线图模型在训练集(影像组学:AUC 0.86;列线图:AUC 0.88)和测试集(影像组学:AUC 0.83;列线图:AUC 0.84)中均显示出更好的校准和验证表现。决策曲线显示,当阈值概率为0.15至0.9时,列线图模型表现优于临床模型。数据结论:基于术前MRI建立的列线图模型具有出色的乳腺癌TIL无创评估能力。证据等级:4;技术效能阶段:2。
Evaluating tumor-infiltrating lymphocytes (TILs) in patients with breast cancer using radiomics has been rarely explored.
To establish a radiomics nomogram based on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for preoperatively evaluating TIL level. STUDY TYPE: Retrospective. POPULATION: A total of 154 patients with breast cancer were divided into a training cohort (N = 87) and a test cohort (N = 67), who were further divided into low TIL (<50%) and high TIL ( 50%) subgroups according to the histopathological results. FIELD STRENGTH/SEQUENCE: 3.0 T; axial T2-weighted imaging (fast spin echo), diffusion-weighted imaging (spin echo-echo planar imaging), and the volume imaging for breast assessment DCE sequence (gradient recalled echo). ASSESSMENT: A radiomics signature was developed from the training dataset and independent risk factors were selected by multivariate logistic regression to build a clinical model. A nomogram model was built by combining radiomics score and risk factors. The performance of the nomogram was assessed using calibration curves and decision curves. The area under the receiver operating characteristic (ROC) curve, accuracy, sensitivity, and specificity were calculated. STATISTICAL TESTS: The least absolute shrinkage and selection operator, univariate and multivariate logistic regression analysis, t-tests and chi-squared tests or Fisher's exact test, Hosmer-Lemeshow test, ROC analysis, and decision curve analysis were conducted. P < 0.05 was considered statistically significant.
The radiomics signature and nomogram model exhibited better calibration and validation performance in the training (radiomics: area under the curve [AUC] 0.86; nomogram: AUC 0.88) and test (radiomics: AUC 0.83; nomogram: AUC 0.84) datasets compared with clinical model (training: AUC 0.76; test: AUC 0.72). The decision curve demonstrated that the nomogram model exhibited better performance than the clinical model, with a threshold probability between 0.15 and 0.9. DATA CONCLUSION: The nomogram model based on preoperative MRI exhibited an excellent ability for the noninvasive evaluation of TILs in breast cancer. LEVEL OF EVIDENCE: 4 TECHNICAL EFFICACY STAGE: 2.
MEMBER ACCOUNT
登录成功会直接打开下一页。